Diabetes Refills

Yes. California Business and Professions Code Section 2290.5 permits licensed physicians to prescribe medications via synchronous video telehealth without a prior in-person visit. TeleDirectMD\'s California-licensed board-certified Family Medicine physician reviews your most recent HbA1c, kidney function (eGFR), blood glucose logs, and medication adherence before authorizing refills for stable established Type 2 diabetes. Metformin, GLP-1 agonists (for T2DM), SGLT2 inhibitors, and sulfonylureas are in scope. Self pay is $79; Aetna is in-network effective April 30, 2026.

No. TeleDirectMD prescribes GLP-1 receptor agonists including semaglutide (Ozempic) and tirzepatide (Mounjaro) for Type 2 diabetes glycemic control only. The physician does not prescribe semaglutide (Wegovy) or tirzepatide (Zepbound) for weight loss in the absence of a Type 2 diabetes diagnosis. Patients seeking weight-loss GLP-1 therapy without Type 2 diabetes should consult a physician with obesity medicine expertise.

The ADA Standards of Medical Care in Diabetes 2024–2025 recommend an HbA1c target of less than 7% for most non-pregnant adults with T2DM. A higher target of less than 8% is appropriate for adults with limited life expectancy, extensive comorbidities, or history of significant hypoglycemia. A more stringent target of less than 6.5% may be considered for newly diagnosed younger patients if safely achievable. The physician individualizes targets based on your clinical situation.

Type 2 diabetes affects approximately 9.2% of California adults — about 2.9 million people — per the California Department of Public Health (CDPH) Chronic Disease Surveillance and CHIS 2023 data. An additional 35% of California adults have prediabetes. Latino Californians have the highest T2DM prevalence at approximately 13.5%. The CDPH Diabetes Prevention Program reports that T2DM-related hospitalizations cost California\'s healthcare system more than $3.2 billion annually.

The physician requires an HbA1c within the past 3–6 months (depending on control status) and an eGFR within the past 12 months before authorizing refills. For SGLT2 inhibitors, eGFR must be ≥20 (dapagliflozin) or ≥25 (empagliflozin) for safety. For metformin, eGFR must be ≥30. A urine albumin-to-creatinine ratio for diabetic nephropathy screening is reviewed annually. Labs available through Quest Diagnostics, LabCorp, and CDPH-funded community health centers throughout California.

SGLT2 inhibitors — empagliflozin (Jardiance) and dapagliflozin (Farxiga) — provide proven cardiovascular and kidney benefits beyond glycemic control. The EMPA-REG OUTCOME trial showed empagliflozin reduced cardiovascular death by 38% in T2DM patients with established ASCVD. The DAPA-CKD trial demonstrated dapagliflozin slowed progression of CKD regardless of T2DM status. ADA 2024 guidelines recommend an SGLT2 inhibitor with proven CV/kidney benefit for T2DM patients with established ASCVD, heart failure, or CKD (eGFR ≥25).

Medi-Cal covers metformin and sulfonylureas at low or no cost-sharing. SGLT2 inhibitors and GLP-1 agonists require prior authorization under Medi-Cal managed care formularies. The California DHCS Diabetes Prevention Program also funds lifestyle intervention programs through enrolled community organizations. TeleDirectMD is not currently enrolled as a Medi-Cal provider — Medi-Cal members can use the $79 self-pay rate or seek care from a Medi-Cal-enrolled primary care provider.

Type 2 diabetes requires urgent in-person care for: symptoms of diabetic ketoacidosis (DKA) — extreme thirst, frequent urination, nausea, vomiting, fruity breath, confusion (can occur in T2DM on SGLT2 inhibitors); severe hypoglycemia with altered consciousness; foot ulcer or wound requiring wound care; newly diagnosed T2DM in a patient requiring comprehensive baseline evaluation; or HbA1c >10% without recent in-person assessment. Type 1 diabetes insulin titration always requires endocrinology care.

Generic metformin ER 500 mg (30–90 tablets) is approximately $4–$15 per month with a GoodRx coupon at California pharmacies including CVS, Walgreens, Walmart, Costco, and Safeway. Metformin is one of the most affordable diabetes medications available. GoodRx coupon prices as of May 2026 — actual prices vary by pharmacy and quantity.

No. Type 1 diabetes insulin titration — including complex multiple daily injection regimens, insulin pump management, and closed-loop systems — requires endocrinology expertise and is outside the scope of TeleDirectMD. TeleDirectMD treats Type 2 diabetes only. Adults with Type 1 diabetes should maintain care with an endocrinologist. TeleDirectMD can assist with non-insulin comorbidity management in T1DM patients but will not prescribe or titrate insulin for Type 1 diabetes.

California Assembly Bill 744 (2019), codified in Insurance Code §10123.85, requires commercial health plans to reimburse telehealth diabetes management visits on the same basis as in-person care. Parity applies when TeleDirectMD is in-network with your plan. Aetna commercial (active April 30, 2026) and UnitedHealthcare Commercial (active May 29, 2026) are in-network in California. Verify your specific plan eligibility before booking.

SGLT2 inhibitors carry a rare but serious risk of euglycemic diabetic ketoacidosis (DKA), which can occur at normal blood glucose levels — making it harder to recognize than classical DKA. Risk is higher during prolonged fasting, major surgery, severe illness, or significant volume depletion. The physician counsels all patients starting SGLT2 inhibitors to hold the medication 3–4 days before elective surgery and to seek emergency evaluation for nausea, vomiting, or abdominal pain. SGLT2 inhibitors are contraindicated in Type 1 diabetes.